Literature DB >> 2187500

Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1.

V S Kalyanaraman1, V Rodriguez, F Veronese, R Rahman, P Lusso, A L DeVico, T Copeland, S Oroszlan, R C Gallo, M G Sarngadharan.   

Abstract

We have previously shown that the cell line 6D5(451) chronically infected with the HIV-1 isolate HTLV-III(451), secretes the HIV-1 envelope glycoproteins gp120 and gp160 in the extracellular medium. The HTLV-III(451) gp120 and gp160 were purified by sequential affinity chromatographic steps using a monoclonal antibody to HIV-1 gp41 and an anti-HIV-1-positive human serum. Amino acid sequence analysis of gp120 and gp160 showed the loss of the signal peptide. Digestion of the purified gp120 and gp160 with endoglycosidases revealed that both proteins are heavily glycosylated and contain complex carbohydrates, in contrast to the intracellular form of gp160 which has been shown to contain mannose-rich immature sugars. Competitive binding analysis showed that while both gp120 and gp160 bind CD4, the affinity of gp160 was five times lower than that of gp120. Both gp120 and gp160 inhibited syncytia formation by HIV-1-infected cells when mixed with CD4+ cells. Furthermore, both gp120 and gp160 had strong mitogenic effects on the T cells from HIV-1-infected gibbons but not on cells from uninfected gibbons.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2187500     DOI: 10.1089/aid.1990.6.371

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  26 in total

1.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

3.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

Authors:  S L Buge; E Richardson; S Alipanah; P Markham; S Cheng; N Kalyan; C J Miller; M Lubeck; S Udem; J Eldridge; M Robert-Guroff
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Functional tolerance of the human immunodeficiency virus type 1 envelope signal peptide to mutations in the amino-terminal and hydrophobic regions.

Authors:  H Ellerbrok; L D'Auriol; C Vaquero; M Sitbon
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

5.  Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

Authors:  J R Mascola; M K Louder; T C VanCott; C V Sapan; J S Lambert; L R Muenz; B Bunow; D L Birx; M L Robb
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.

Authors:  L Jean Patterson; Seraphin Kuate; Mara Daltabuit-Test; Qingsheng Li; Peng Xiao; Katherine McKinnon; Janet DiPasquale; Anthony Cristillo; David Venzon; Ashley Haase; Marjorie Robert-Guroff
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

7.  Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.

Authors:  Maria Leavitt; Eun Ju Park; Igor A Sidorov; Dimiter S Dimitrov; Gerald V Quinnan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

8.  Successful hematopoietic reconstitution with transplantation of erythrocyte-depleted allogeneic human umbilical cord blood cells in a child with leukemia.

Authors:  R N Pahwa; A Fleischer; S Than; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

9.  Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus.

Authors:  M G Lewis; J Yalley-Ogunro; J J Greenhouse; T P Brennan; J B Jiang; T C VanCott; Y Lu; G A Eddy; D L Birx
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.

Authors:  Jun Zhao; Joel Pinczewski; Victor R Gómez-Román; David Venzon; V S Kalyanaraman; Phillip D Markham; Kristine Aldrich; Matthew Moake; David C Montefiori; Yuanmei Lou; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.